Diabetes, TZDs, and Bone: A Review of the Clinical Evidence
نویسنده
چکیده
Evidence from rodent and in vitro models suggests that activation of PPAR-gamma by thiazolidinediones (TZDs) causes increased bone marrow adiposity and decreased osteoblastogenesis, resulting in bone loss. TZDs are prescribed for the treatment of diabetes, providing an opportunity to determine whether PPAR-gamma activation also impacts bone in humans. In addition, since type 2 diabetes is associated with higher fracture risk, an understanding of the clinical impact of TZDs on bone is needed to guide fracture prevention efforts in this population. This review summarizes current findings regarding type 2 diabetes and increased fracture risk and then considers the available evidence regarding TZD use and bone metabolism in humans.
منابع مشابه
Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis
Clinical evidence indicates that bone status is affected in patients with type 2 diabetes mellitus (T2DM). Regardless of normal or even high bone mineral density, T2DM patients have increased risk of fractures. One class of antidiabetic drugs, thiazolidinediones (TZDs), causes bone loss and further increases facture risk, placing TZDs in the category of drugs causing secondary osteoporosis. Ris...
متن کاملWill Statin Use Prevent Fracture of Type 2 Diabetes Associated with Thiazolidinedione Treatment? A Mini-Review and a Hypothesis
Thiazolidinediones (TZDs) are a multi-effective anti-glycemic drug for type 2 diabetes. Recent clinical trials suggest TZDs are associated with bone loss or fracture in older diabetic women. Diabetic women exhibit more rapid bone loss despite the higher baseline bone mineral density. The higher fracture risk of type 2 diabetes may be associated with neural and vascular complications, or the fra...
متن کاملACHIEVEMENTS AND ADVANCES IN DIABETES RESEARCH OVER A QUARTER OF A CENTURY: A REVIEW OF THE AVAILABLE EVIDENCE
Background: Endocrinology and Metabolism Research Institute (EMRI) is one of the largest research institutes in Iran, which has been established to develop research strategies and manage endocrine and metabolic diseases such as diabetes. The purpose of this report is to review and summarize research activities related to diabetes over a quarter of a century at EMRI. Methods: A comprehensive se...
متن کاملTZDs and Bone: A Review of the Recent Clinical Evidence
Over the past two years, evidence has emerged that the currently available thiazolidinediones (TZDs), rosiglitazone, and pioglitazone have negative skeletal consequences, at least in women, which are clinically important. Increased fracture risk in women, but not men, was reported for both TZDs, based on analyses of adverse event reports from clinical trials. In short-term clinical trials in wo...
متن کاملPeroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives
Since their initial availability in 1997, the thiazolidinediones (TZDs) have become one of the most commonly prescribed classes of medications for type 2 diabetes. In addition to glucose control, the TZDs have a number of pleiotropic effects on myriad traditional and non-traditional risk factors for diabetes. TZDs may benefit cardiovascular parameters, such as lipids, blood pressure, inflammato...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- PPAR Research
دوره 2006 شماره
صفحات -
تاریخ انتشار 2006